Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 1/20 | 0.41 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.41 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | PYCR1 | P32322 | 1/20 | 0.40 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.37 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.37 |
| ▸ | HDAC3 | O15379 | 2/20 | 0.37 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.37 |
| ▸ | HDAC2 | Q92769 | 2/20 | 0.37 |
| ▸ | SLC2A1 | P11166 | 1/20 | 0.37 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | MGLL | Q99685 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12991616 | 0.98 | LMNA (0.42) | CYP1A2CYP2D6CYP2C19LMNAPYCR1 | |
| SCHEMBL13108720 | 0.98 | LMNA (0.42) | CYP1A2CYP2D6CYP2C19LMNAPYCR1 | |
| SCHEMBL17666735 | 0.94 | PYCR1 (0.41) | CYP1A2CYP2D6CYP2C19LMNAPYCR1 | |
| SCHEMBL6678858 | 0.89 | OPRM1 (0.44) | OPRM1SLC2A1NR1I2 | |
| SCHEMBL19224211 | 0.88 | GLB1 (0.38) | CYP1A2CYP2D6CYP2C19LMNAPYCR1 | |
| SCHEMBL9137197 | 0.87 | SLC2A1 (0.44) | LMNAOPRM1SLC2A1NR1I2 | |
| SCHEMBL6684351 | 0.87 | SLC2A1 (0.44) | LMNAOPRM1SLC2A1NR1I2 | |
| SCHEMBL10273168 | 0.85 | PYCR1 (0.43) | CYP1A2PYCR1ALOX5KMT2A | |
| SCHEMBL16186720 | 0.85 | PYCR1 (0.43) | CYP1A2PYCR1ALOX5KMT2A | |
| SCHEMBL16411173 | 0.85 | PYCR1 (0.43) | CYP1A2PYCR1ALOX5KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20190040008-A1 | SMALL MOLECULE LFA-1 INHIBITORS | ALLOCYTE PHARMACEUTICALS AG (CH) | 2019-02-07 | — | — | US | disclosed |
| EP-2665797-B1 | LIQUID CRYSTALLINE MEDIA, COMPONENTS FOR HIGH FREQUENCY TECHNOLOGY AND MESOGENIC COMPOUNDS | MERCK PATENT GMBH (DE) | 2016-11-23 | — | — | EP | disclosed |
| EP-2688980-B1 | MESOGEN COMPOUNDS, LIQUID CRYSTALLINE MEDIA AND COMPONENTS FOR HIGH FREQUENCY TECHNOLOGY | MERCK PATENT GMBH (DE) | 2016-11-02 | — | — | EP | disclosed |
| WO-2010019536-A1 | THERAPEUTIC COMPOUNDS | ALLERGAN, INC. (US) | 2010-02-18 | — | — | WO | disclosed |
| US-7550448-B2 | Glaucoma; 3-halopyrrolidine compounds; prostaglandin EP2 receptor modulators | ALLERGAN, INC. (US) | 2009-06-23 | — | — | US | disclosed |
| US-20080045596-A1 | Ep2 Receptor Agonists | ASTERAND, INC. | 2008-02-21 | — | — | US | disclosed |
| US-20070281981-A1 | Glaucoma; 3-substituted pyrrolidine compounds; prostaglandin receptor modulators | ALLERGAN, INC. | 2007-12-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070281981-A1 | Glaucoma; 3-substituted pyrrolidine compounds; prostaglandin receptor modulators | PTGIR, PTGIS, PTGS1 | CYP1A2 1597/4885CYP2D6 1573/4885CYP2C19 856/4885 |
| US-20190040008-A1 | SMALL MOLECULE LFA-1 INHIBITORS | ICAM1, VCAM1, ITGB1 | CYP1A2 3901/4885CYP2D6 4299/4885CYP2C19 4595/4885 |
| US-20080045596-A1 | Ep2 Receptor Agonists | PTGER2, PTGER1, PTGER3 | CYP1A2 315/4885CYP2D6 706/4885CYP2C19 788/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.